Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology

David A. Shapiro, Sean Renock, Elaine Arrington, Louis A. Chiodo, Li Xin Liu, David R. Sibley, Bryan L. Roth, Richard Mailman

Research output: Contribution to journalArticle

717 Citations (Scopus)

Abstract

Atypical antipsychotic drugs have revolutionized the treatment of schizophrenia and related disorders. The current clinically approved atypical antipsychotic drugs are characterized by having relatively low affinities for D2-dopamine receptors and relatively high affinities for 5-HT 2A serotonin receptors (5-HT, 5-hydroxytryptamine (serotonin)). Aripiprazole (OPC-14597) is a novel atypical antipsychotic drug that is reported to be a high-affinity D2-dopamine receptor partial agonist. We now provide a comprehensive pharmacological profile of aripiprazole at a large number of cloned G protein-coupled receptors, transporters, and ion channels. These data reveal a number of interesting and potentially important molecular targets for which aripiprazole has affinity. Aripiprazole has highest affinity for h5-HT2B-, hD2L-, and hD3- dopamine receptors, but also has significant affinity (5-30 nM) for several other 5-HT receptors (5-HT1A, 5-HT2A, 5-HT7), as well as α1A-adrenergic and hH1-histamine receptors. Aripiprazole has less affinity (30-200 nM) for other G protein-coupled receptors, including the 5-HT1D, 5-HT2C, α1B-, α2A-, α2B-, α2C-, β1-, and β2-adrenergic, and H3-histamine receptors. Functionally, aripiprazole is an inverse agonist at 5-HT2B receptors and displays partial agonist actions at 5-HT2A, 5-HT2C, D3, and D4 receptors. Interestingly, we also discovered that the functional actions of aripiprazole at cloned human D2-dopamine receptors are cell-type selective, and that a range of actions (eg agonism, partial agonism, antagonism) at cloned D2-dopamine receptors are possible depending upon the cell type and function examined. This mixture of functional actions at D 2-dopamine receptors is consistent with the hypothesis proposed by Lawler et al (1999) that aripiprazole has 'functionally selective' actions. Taken together, our results support the hypothesis that the unique actions of aripiprazole in humans are likely a combination of 'functionally selective' activation of D2 (and possibly D3)-dopamine receptors, coupled with important interactions with selected other biogenic amine receptors - particularly 5-HT receptor subtypes (5-HT1A, 5-HT2A).

Original languageEnglish (US)
Pages (from-to)1400-1411
Number of pages12
JournalNeuropsychopharmacology
Volume28
Issue number8
DOIs
StatePublished - Aug 1 2003

Fingerprint

Antipsychotic Agents
Pharmacology
Serotonin
Dopamine D2 Receptors
Serotonin Receptors
Dopamine Receptors
G-Protein-Coupled Receptors
Adrenergic Agents
Biogenic Amines Receptors
Receptor, Serotonin, 5-HT2B
Aripiprazole
Histamine H3 Receptors
Dopamine D3 Receptors
Receptor, Serotonin, 5-HT2A
Histamine Receptors
Dopamine Agonists
Ion Channels
Schizophrenia

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L. X., Sibley, D. R., ... Mailman, R. (2003). Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology, 28(8), 1400-1411. https://doi.org/10.1038/sj.npp.1300203
Shapiro, David A. ; Renock, Sean ; Arrington, Elaine ; Chiodo, Louis A. ; Liu, Li Xin ; Sibley, David R. ; Roth, Bryan L. ; Mailman, Richard. / Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. In: Neuropsychopharmacology. 2003 ; Vol. 28, No. 8. pp. 1400-1411.
@article{b3d483b2237f420ba45190dc357fee94,
title = "Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology",
abstract = "Atypical antipsychotic drugs have revolutionized the treatment of schizophrenia and related disorders. The current clinically approved atypical antipsychotic drugs are characterized by having relatively low affinities for D2-dopamine receptors and relatively high affinities for 5-HT 2A serotonin receptors (5-HT, 5-hydroxytryptamine (serotonin)). Aripiprazole (OPC-14597) is a novel atypical antipsychotic drug that is reported to be a high-affinity D2-dopamine receptor partial agonist. We now provide a comprehensive pharmacological profile of aripiprazole at a large number of cloned G protein-coupled receptors, transporters, and ion channels. These data reveal a number of interesting and potentially important molecular targets for which aripiprazole has affinity. Aripiprazole has highest affinity for h5-HT2B-, hD2L-, and hD3- dopamine receptors, but also has significant affinity (5-30 nM) for several other 5-HT receptors (5-HT1A, 5-HT2A, 5-HT7), as well as α1A-adrenergic and hH1-histamine receptors. Aripiprazole has less affinity (30-200 nM) for other G protein-coupled receptors, including the 5-HT1D, 5-HT2C, α1B-, α2A-, α2B-, α2C-, β1-, and β2-adrenergic, and H3-histamine receptors. Functionally, aripiprazole is an inverse agonist at 5-HT2B receptors and displays partial agonist actions at 5-HT2A, 5-HT2C, D3, and D4 receptors. Interestingly, we also discovered that the functional actions of aripiprazole at cloned human D2-dopamine receptors are cell-type selective, and that a range of actions (eg agonism, partial agonism, antagonism) at cloned D2-dopamine receptors are possible depending upon the cell type and function examined. This mixture of functional actions at D 2-dopamine receptors is consistent with the hypothesis proposed by Lawler et al (1999) that aripiprazole has 'functionally selective' actions. Taken together, our results support the hypothesis that the unique actions of aripiprazole in humans are likely a combination of 'functionally selective' activation of D2 (and possibly D3)-dopamine receptors, coupled with important interactions with selected other biogenic amine receptors - particularly 5-HT receptor subtypes (5-HT1A, 5-HT2A).",
author = "Shapiro, {David A.} and Sean Renock and Elaine Arrington and Chiodo, {Louis A.} and Liu, {Li Xin} and Sibley, {David R.} and Roth, {Bryan L.} and Richard Mailman",
year = "2003",
month = "8",
day = "1",
doi = "10.1038/sj.npp.1300203",
language = "English (US)",
volume = "28",
pages = "1400--1411",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "8",

}

Shapiro, DA, Renock, S, Arrington, E, Chiodo, LA, Liu, LX, Sibley, DR, Roth, BL & Mailman, R 2003, 'Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology', Neuropsychopharmacology, vol. 28, no. 8, pp. 1400-1411. https://doi.org/10.1038/sj.npp.1300203

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. / Shapiro, David A.; Renock, Sean; Arrington, Elaine; Chiodo, Louis A.; Liu, Li Xin; Sibley, David R.; Roth, Bryan L.; Mailman, Richard.

In: Neuropsychopharmacology, Vol. 28, No. 8, 01.08.2003, p. 1400-1411.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology

AU - Shapiro, David A.

AU - Renock, Sean

AU - Arrington, Elaine

AU - Chiodo, Louis A.

AU - Liu, Li Xin

AU - Sibley, David R.

AU - Roth, Bryan L.

AU - Mailman, Richard

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Atypical antipsychotic drugs have revolutionized the treatment of schizophrenia and related disorders. The current clinically approved atypical antipsychotic drugs are characterized by having relatively low affinities for D2-dopamine receptors and relatively high affinities for 5-HT 2A serotonin receptors (5-HT, 5-hydroxytryptamine (serotonin)). Aripiprazole (OPC-14597) is a novel atypical antipsychotic drug that is reported to be a high-affinity D2-dopamine receptor partial agonist. We now provide a comprehensive pharmacological profile of aripiprazole at a large number of cloned G protein-coupled receptors, transporters, and ion channels. These data reveal a number of interesting and potentially important molecular targets for which aripiprazole has affinity. Aripiprazole has highest affinity for h5-HT2B-, hD2L-, and hD3- dopamine receptors, but also has significant affinity (5-30 nM) for several other 5-HT receptors (5-HT1A, 5-HT2A, 5-HT7), as well as α1A-adrenergic and hH1-histamine receptors. Aripiprazole has less affinity (30-200 nM) for other G protein-coupled receptors, including the 5-HT1D, 5-HT2C, α1B-, α2A-, α2B-, α2C-, β1-, and β2-adrenergic, and H3-histamine receptors. Functionally, aripiprazole is an inverse agonist at 5-HT2B receptors and displays partial agonist actions at 5-HT2A, 5-HT2C, D3, and D4 receptors. Interestingly, we also discovered that the functional actions of aripiprazole at cloned human D2-dopamine receptors are cell-type selective, and that a range of actions (eg agonism, partial agonism, antagonism) at cloned D2-dopamine receptors are possible depending upon the cell type and function examined. This mixture of functional actions at D 2-dopamine receptors is consistent with the hypothesis proposed by Lawler et al (1999) that aripiprazole has 'functionally selective' actions. Taken together, our results support the hypothesis that the unique actions of aripiprazole in humans are likely a combination of 'functionally selective' activation of D2 (and possibly D3)-dopamine receptors, coupled with important interactions with selected other biogenic amine receptors - particularly 5-HT receptor subtypes (5-HT1A, 5-HT2A).

AB - Atypical antipsychotic drugs have revolutionized the treatment of schizophrenia and related disorders. The current clinically approved atypical antipsychotic drugs are characterized by having relatively low affinities for D2-dopamine receptors and relatively high affinities for 5-HT 2A serotonin receptors (5-HT, 5-hydroxytryptamine (serotonin)). Aripiprazole (OPC-14597) is a novel atypical antipsychotic drug that is reported to be a high-affinity D2-dopamine receptor partial agonist. We now provide a comprehensive pharmacological profile of aripiprazole at a large number of cloned G protein-coupled receptors, transporters, and ion channels. These data reveal a number of interesting and potentially important molecular targets for which aripiprazole has affinity. Aripiprazole has highest affinity for h5-HT2B-, hD2L-, and hD3- dopamine receptors, but also has significant affinity (5-30 nM) for several other 5-HT receptors (5-HT1A, 5-HT2A, 5-HT7), as well as α1A-adrenergic and hH1-histamine receptors. Aripiprazole has less affinity (30-200 nM) for other G protein-coupled receptors, including the 5-HT1D, 5-HT2C, α1B-, α2A-, α2B-, α2C-, β1-, and β2-adrenergic, and H3-histamine receptors. Functionally, aripiprazole is an inverse agonist at 5-HT2B receptors and displays partial agonist actions at 5-HT2A, 5-HT2C, D3, and D4 receptors. Interestingly, we also discovered that the functional actions of aripiprazole at cloned human D2-dopamine receptors are cell-type selective, and that a range of actions (eg agonism, partial agonism, antagonism) at cloned D2-dopamine receptors are possible depending upon the cell type and function examined. This mixture of functional actions at D 2-dopamine receptors is consistent with the hypothesis proposed by Lawler et al (1999) that aripiprazole has 'functionally selective' actions. Taken together, our results support the hypothesis that the unique actions of aripiprazole in humans are likely a combination of 'functionally selective' activation of D2 (and possibly D3)-dopamine receptors, coupled with important interactions with selected other biogenic amine receptors - particularly 5-HT receptor subtypes (5-HT1A, 5-HT2A).

UR - http://www.scopus.com/inward/record.url?scp=0042887023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042887023&partnerID=8YFLogxK

U2 - 10.1038/sj.npp.1300203

DO - 10.1038/sj.npp.1300203

M3 - Article

C2 - 12784105

AN - SCOPUS:0042887023

VL - 28

SP - 1400

EP - 1411

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 8

ER -

Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003 Aug 1;28(8):1400-1411. https://doi.org/10.1038/sj.npp.1300203